ganitumab + sorafenib

*ganitumab + sorafenib* is an investigational combination therapy comprising **ganitumab**, a fully human monoclonal antibody targeting the *insulin-like growth factor 1 receptor (IGF1R)*, and **sorafenib**, an oral multikinase inhibitor that targets oncogenic kinases including *Raf kinase* and various *receptor tyrosine kinases* (notably VEGFR and PDGFR). Ganitumab functions by blocking IGF1R signaling and thus inhibits tumor proliferation and survival, while sorafenib interrupts multiple signaling pathways involved in tumor cell proliferation and angiogenesis. This combination has been studied in early-phase clinical trials for patients with advanced solid tumors, including hepatocellular carcinoma and other refractory cancers, and has shown acceptable safety and preliminary antitumor activity[1][3].